ReviewMolecules (Basel, Switzerland)2025
Small-Molecule Tyrosinase Inhibitors for Treatment of Hyperpigmentation.
Review in Molecules (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Strategy and efficiency-redefined discovery of novel nanomolar tyrosinase inhibitors: AI de novo molecular generation + expert-guided structural optimization.Journal of advanced research · 2026Article
- Organ-Specific Targeted Phenolic Profiling, Antioxidant, and Enzyme-Inhibitory Activities of the Gypsophilous EndemicMolecules (Basel, Switzerland) · 2026Article
- Discovery of TYR inhibitors from de novo molecular generation to dual-track lead optimization: "Competition" between AI and chemists.Science advances · 2026Article
- Development of new coumarin-piperazine-N-phenylacetamid derivatives as potent tyrosinase inhibitors: In vitro and in silico evaluations.Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2026Article
- Synthesis and integrative multimodal evaluation of cholic acid-based hydrazone conjugates: in vitro, in silico, and in vivo studies.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Microalgal Exosome-like Nanovesicles fromMarine drugs · 2026Article
- Synthesis, in vitro, and in silico studies of 4-chlorophenyl-sulfonyl Indole based thiosemicarbazones as competitive α-glucosidase inhibitors.Scientific reports · 2025Article
- Review
- Hydroxyketone Tyrosinase Inhibitors: Mechanism of Action, Applications and Perspectives in Depigmentation and Melanoma Therapy.Molecules (Basel, Switzerland) · 2025Review
- Structure-based design and evaluation of tyrosinase inhibitors targeting both human and mushroom isozymes.RSC medicinal chemistry · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Increasing attention is being focused on skin health currently, especially the excessive deposition of melanin in the skin. Tyrosinase, the rate-limiting enzyme in melanin biosynthesis, is a crucial enzyme in melanin synthesis. However, existing tyrosinase inhibitors pose some degree of toxicity to humans. Therefore, the development of more efficient and low-toxicity tyrosinase inhibitors is urgently needed. This review briefly depicts the melanin biosynthesis process and the crystal structure and catalytic mechanism of tyrosinase. The latest research progress regarding small-molecule tyrosinase inhibitors is also reviewed. Moreover, the structure-function relationships are analyzed and summarized. This is expected to provide new and more scientific insights to enable researchers to explore safer and more potent tyrosinase inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.